Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The FDA grants separate approvals for separate indications, which allows Novo Nordisk to market the same molecule under different names
These changes likely result from the combination of weight loss, improved blood sugar control, and the medications direct effects on metabolic processes
Retatrutide (LY3437943) is a novel synthetic peptide engineered as a single-molecule triple agonist targeting three distinct metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors
GHK-Cu works through cumulative gene expression changes, not acute blood levels
These data suggest that a mGIPR-Ab/GLP-1 peptideantibody conjugate may act on a different population of cells or via distinct molecular mechanism(s) compared to GIPR agonists like tirzepatide
US$ 29.19
US$ 22.32
US$ 29.21
US$ 28.74
US$ 29.02
